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Background
Adenocarcinoma of the small bowel is relatively rare 
malignancy which carries a poor prognosis. The American 
Cancer Society estimated 6,960 new cases of small 
intestinal cancer diagnosed in the year 2010 (1). According 
to the National Cancer Data Base, adenocarcinoma 
represented 36.9% of all patients with small bowel 
malignancies (2). Despite recent technical advances in 
imaging and endoscopy (3), delays in diagnosis is common 
and the majority (58%) of patients present with advanced 
Stage III or IV disease (2). Small bowel adenocarcinoma 
(SBA) also has the poorest prognosis among small bowel 
cancer histologies, with relative five-year observed survival 
rate of 32.5%, compared to 39.9% for stromal tumors, 
49.6% for lymphomas and 64.6% for carcinoids. The 
median survival and 5-year disease specific survival (DSS) 
rates of patients with stage IV or recurrent disease are 
9 months and 4.2%, respectively. For patients with stage III 
disease, median survival is 29.8 months and 5-year survival 
rate is only 35.4% (4). In addition, 5-year DSS is worse for 
patients with duodenal adenocarcinoma (28.2%) compared 
to those with jejunal (37.6%) or ileal (37.8%) primaries. 
Poorly differentiated tumors also carry a worse prognosis 
with median survival times of 11.1 months compared to 
28.6 months for those with well-differentiated tumors. 
Literature regarding treatment options in the adjuvant 
and metastatic setting for small bowel adenocarcinoma is 
limited. There is an urgent need to evaluate novel strategies 
to treat these rare malignancies. We hereby report the case 
of our patient with recurrent duodenal adenocarcinoma 
with a disease-free survival of more than five years after 
treatment with chemotherapy and an antiangiogenic agent, 
bevacizumab.
Case report
An otherwise healthy 45-year-old man presented with 
significant abdominal bloating and tarry stools and 
was found to have a mass in the third portion of the 
duodenum. Computed tomography (CT) scan revealed 
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concentric wall thickening of the distal duodenum and 
a mildly enlarged aortocaval lymph node. A Whipple 
procedure was performed and identified a tumor in the 
third portion of the duodenum. Pathologic examination of 
the 2.5 cm duodenal mass revealed a moderately to poorly 
differentiated duodenal adenocarcinoma with focal signet 
ring features. Metastatic carcinoma was found in three of 
five periduodenal lymph nodes and one omental implant. 
Six weeks following surgery, the patient was started 
on adjuvant chemotherapy with modified FOLFOX6 for 
eight doses followed by consolidative chemoradiation. Thirty 
months following surgery, he developed a local recurrence. 
CT imaging revealed a soft tissue mass, measuring 4.2 cm × 
2.4 cm anterior to the left renal vein and immediately 
posterior to the superior mesenteric artery. His CEA 
level was elevated at 16.3 and treatment was started with 
FOLFOX6 and Bevacizumab with subsequent reduction 
of the tumor size to 2.4 cm × 1.8 cm after three months 
(Figure 1). After 12 doses of FOLFOX6, positron emission 
tomography (PET) showed a residual area without increased 
FDG uptake, corresponding to the tumor seen on imaging. 
The patient’s chemotherapy was switched to capecitabine 
and bevacizumab due to oxaliplatin-related neuropathy. 
Maintenance chemotherapy was given over a duration of 
two years after he achieved a complete radiologic and PET 
response to therapy. The patient continues to be disease-
free 8 years since his recurrence. 
Discussion
Currently, there is no consensus as to the benefit of, and 
the optimal regimen for, adjuvant therapy for patients with 
small bowel adenocarcinoma. The rarity of the disease has 
limited the ability to carry out prospective clinical trials 
and the optimal regimen remains undefined. Retrospective 
studies reported no significant survival advantage for 
patients who received adjuvant chemotherapy after resection 
of their primary tumors (5-7). In fact, patients who received 
adjuvant radiotherapy had shorter median survival times 
at 21.6 months compared to 49.9 months for those who 
did not (6). However, a multivariate analysis of one of these 
retrospective studies demonstrated that the use of adjuvant 
chemotherapy improved disease-free survival, and in patients 
considered “high risk” (lymph node ratio ≥10%), adjuvant 
therapy appear to improve survival (7). Despite a lack of 
clear evidence supporting its use, the National Cancer 
Data Base [1985-2005] reported an increase in the use of 
adjuvant chemotherapy from 8.1% in 1985 to 22.5% in 
2005 (2). Chemotherapeutic regimens have included 5-FU 
or capecitabine with or without a platinum compound, 
such as oxaliplatin (7). Some of these retrospective data are 
summarized in Table 1.
Two years after his last adjuvant chemotherapy, our 
patient had a radiographic recurrence of duodenal 
adenocarcinoma with a concurrent rise in his CEA. He then 
displayed a complete radiographic response to systemic 
Figure 1 Significant radiologic response of the recurrent duodenal adenocarcinoma following 2 cycles of bevacizumab and FOLFOX.
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chemotherapy using FOLFOX6 and bevacizumab, followed 
by maintenance capecitabine and bevacizumab for a period 
of two years. Remarkably, he continues to be disease-free 
eight years after his recurrence.
For patients with unresected or metastatic SBA, 
there was a significant improvement in overall survival 
with systemic therapy compared to those who received 
no therapy (12 vs. 2 months; P=0.02) based on the MD 
Anderson retrospective study (5). Older fluoropyrimidine-
based regimens, such as 5FU, doxorubicin with mitomycin 
yielded a disappointing 18% response rate and an 8-month 
median survival (8). Two of the 38 evaluable patients had 
complete radiologic responses. More recently, oxaliplatin 
plus capecitabine produced a 50% response rate (3 complete 
responses) with a 20.4-month median survival among 
31 patients with small bowel and ampullary adenocarcinomas (9). 
Excluding the patients with ampullary tumors, response rate 
was 61% for the 18 patients with SBA. Further support for 
the use of oxaliplatin-based regimen in SBA arose from a 
retrospective French multicenter study (10). FOLFOX was 
associated with a 34% response rate, median progression-
free survival of 6.9 months and median OS of 17.8 months. 
Thus, oxaliplatin-based chemotherapy has been suggested 
as a new standard for the treatment of metastatic or 
recurrent SBA (Table 2).
This is the first case report of bevacizumab used 
both with first-line FOLFOX, and with maintenance 
capecitabine, in a patient with SBA resulting in a complete 
Table 1 Selected retrospective data regarding adjuvant treatment of small bowel adenocarcinoma
Author/
Publication




Curative resection of 
duodenal adenocarcinoma








No impact of 
chemoradiation on 





Margin negative surgical 
resection of small 
bowel adenocarcinoma 
(duodenum 67%, Jejunum 
20%, Ileum 13%)





or without radiation 
[28] and radiation 
only [2]
In multivariate 
analysis, use of 
adjuvant therapy 
was associated with 
improved DFS not OS.
In high risk patients 
(LN ratio ≥10%) 
adjuvant therapy 
improved OS but not 
DFS  (P=0.04)
5-year OS and 
DFS did not differ 
between treatment 
groups.
Suggest use of 
adjuvant therapy 
for curatively 















5-year survival rate 
was 44% and  
median survival for  







local control) does 
not improve overall 
survival at 5 years
Kelsey et al./














5-year survival 57% 
(vs. 44% with surgery 
only. P=0.42, NS). 
Patients with R0 
resection, 5 yr survival 
83% (vs. 53 % in the 
no chemoradiation 
arm, P=0.07)
Local failure rates 
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Table 3 Selected ongoing clinical trials in small bowel adenocarcinoma. Ref: www.clinicaltrials.gov







NCT01202409 Phase II Study of 
Panitumumab Combined 
With Capecitabine and 
Oxaliplatin (CAPOX) in 
Patients With KRAS Wild-
type Locally Advanced or 
Metastatic Adenocarcinoma 
of the Small Bowel or 
Ampulla of Vater
Capecitabine  
750 mg/m2 bid ×  
14 days, Oxaliplatin 
130 mg/m2 day 1 and 
Panitumumab  
9 mg/kg day 1 every 
21 day cycle






NCT00433550 A Phase II Trial of 
Pharmacogenetic-Based 
Dosing of Irinotecan 
(I), Oxaliplatin (O), and 
Capecitabine (C ) as First-Line 
Therapy for Advanced Small 
Bowel Adenocarcinoma
Group 1 (6/6 UGT1A1 
genotype): I (d1)+O 
(d1)+C (d2-15).
Group 2 (6/7): I as 
group 1, Lower doses 
of O and C.
Group 3 (7/7): I, O 
and C at lower doses
II Tumor response 











NCT01208103 Phase II Study of 
Bevacizumab Combined With 
Capecitabine and Oxaliplatin 
(CAPOX) in Patients With 
Advanced Adenocarcinoma 
of the Small Bowel or 
Ampulla of Vater
Capecitabine  
750 mg/m2 bid ×  
14 days, Oxaliplatin 
130 mg/m2 day 1 and 
Bevacizumab  
7.5 mg/kg day 1 every 
21 day cycle








NCT00987766 Phase Ib Trial of Gemcitabine 
and Oxaliplatin (GEMOX) 
With Erlotinib in Patients 
With Advanced Biliary Tract 
Cancer. (includes Pancreatic 
Cancer, Duodenal Cancer, or 
Ampullary Cancer)
Erlotinib by mouth 
daily 6 days 
every other week, 
Gemcitabine IV 
every other week, 
Oxaliplatin IV every 
other week
I MTD and 
recommended 
phase II dose 
































39 Locally advanced 
or metastatic 
SBA or ampullary 
adenocarcinoma
5-FU 600 mg/m2 (days1, 
8, 29, 36), doxorubicin 
30 mg/m2 (days 1, 29) & 
Mitomycin C 10 mg/m2 
(day 1 only)














Capecitabine 750 mg/m2  
BID (Days 1-14) and 
Oxaliplatin 130 mg/m2 
(day 1) every 21 days
52% (3 CR) in 
the 25 metastatic 
patients.
61% in SBA vs. 
33% in ampullary 
adenocarcinoma
20.4 months
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radiologic response and prolonged progression-free 
survival 8 years after his recurrence. Vascular endothelial 
growth factor A (VEGF-A) overexpression was observed 
in 91% of SBA (11). Bevacizumab is an anti-VEGF 
monoclonal  antibody with proven eff icacy in the 
treatment of metastatic colorectal cancer (12). Although 
the mechanism of its efficacy has not been elucidated, 
results indicate that it renders cancer cells more sensitive 
to cytotoxic chemotherapy (13). Malignant epithelial 
cells of the gastrointestinal tract including small bowel 
adenocarcinoma express VEGF mRNA strongly, in 
contrast to normal epithelium, hyperplastic polyps, 
and adenomas (14). A recent study of 54 patients with 
small bowel adenocarcinoma confirmed this finding. 
50 (91%) of these patients’ tissue displayed expression of 
VEGF-A, with high levels of its expression observed in 
44 (81%) patients (11). Thus, there is basic science 
evidence to suggest that bevacizumab may be effective 
in SBA. Clinical success with bevacizumab in SBA was 
reported in 2008 by Tsang et al. (15). A 68-year-old with 
advanced adenocarcinoma of the jejunum received 8 cycles 
of gemcitabine and bevacizumab with regression of disease 
as measured by PET one year after presentation.
In treating this patient’s recurrence, we hypothesized 
that bevacizumab would give added efficacy to the 
standard cytotoxic chemotherapy regimen. As noted above, 
MDACC’s prospective study’s success with capecitabine 
and oxaliplatin for advanced adenocarcinoma of the small 
bowel included 10% of patients who achieved a complete 
radiographic response. Because the chemotherapeutic 
regimens used for this patient’s recurrence also included 
FOLFOX (which includes oxal iplatin)  and,  later, 
capecitabine, it is difficult to ascertain the contribution 
of bevacizumab to his excellent response. Nonetheless, 
we present these findings to propose that bevacizumab 
does warrant further study for treatment of SBA. Table 3 
lists current studies for patients with SBA, including one 
study from MD Anderson utilizing bevacizumab with 
chemotherapy. 
Conclusions
This is an unusual case of a patient with prolonged 
disease-free survival of a recurrent small bowel signet 
ring adenocarcinoma who experienced a complete 
radiologic response to bevacizumab with oxaliplatin-based 
chemotherapy. Further investigation of this regimen is 
warranted. 
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